Please assess the completion status of the following clinical trial:

Trial Title: Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria (MRA011JP patients)~* Of the patients who received the three infusions of MRA at the same dose in the main evaluation period in the previous study and are currently in the continued treatment period~* the patients in whom it is confirmed that the drug is effective and there are no problems with safety (MRA316JP patients)~* Patients who proceed to the blind period and in whom the last observations are done after study completion or withdrawal~* Patients who receive the three infusions in the open-label period and do not meet the criteria for transition to the blind period~Exclusion criteria~* Patients who were not enrolled by 3 months after completion of the previous study~* Patients who have been treated with infliximab or etanercept from completion of the previous study until the start of treatment in this study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).